

Hepatitis B Vaccines **PreHevbrio (3-Antigen) HBV Vaccine**

Prepared by: Maria A. Corcorran, MD, MPH H. Nina Kim, MD, MSc David H. Spach, MD

Last Updated: April 1, 2022

HEPATITIS B ONLINE www.hepatitisB.uw.edu

PreHevBrio (3-Antigen) HBV Vaccine

Indication


- For the prevention of HBV in adults ≥18 years of age

Components

- 10 µg HBs Antigens
- 500 µg Aluminum hydroxide
- Dosing
 - 3 doses (1.0 mL with each dose), given at 0, 1, and 6-months.
- Serious Adverse Events (within 6 months of vaccination)
 - Reported in 2.5%



PreHevbrio: Standard Dosing Schedule





PreHevbrio Hepatitis B Vaccine: Summary of Key Phase 3 Trials
PROTECT: PreHevbrio versus Engerix-B in Adults ≥18 years of age
CONSTANT: 4-arm lot-to-lot study of PreHevbrio versus Engerix-B in adults 18-45 years of age





PreHevbrio versus Engerix-B in Healthy Adults **PROTECT Trial**



PreHevbrio Vaccine vs Engerix-B Vaccine in Adults PROTECT Trial: Design

Design

 Phase 3, double-blind, randomized controlled trial, conducted at multiple sites in the USA, Finland, Canada, and Belgium that compared the safety and immunogenicity of PreHevbrio verus Engerix-B hepatitis B vaccines

• Participants (n = 1,607)


- Ages: ≥18 years
- HBV vaccine naïve
- Exclusions: current or past HBV infection; HIV; HCV; pregnancy; receipt of any live attenuated vaccine within 4 weeks of enrollment; receipt of inactivated vaccine within 2 weeks of enrollment; and uncontrolled comorbidities

Primary End Point

- Anti-HBs seroprotection rate 4 weeks after 3rd dose of PreHevbrio or Engerix-B



PreHevbrio Vaccine vs Engerix-B Vaccine in Adults PROTECT Trial: Design



Vaccine Dosing

PreHevbrio: 1.0 mL dose of 10 µg HBs antigens at weeks 0, 4, and 24 **Engerix-B**: 1 mL dose of 20 µg recombinant HBsAg at weeks 0, 4, and 24




PreHevbrio Vaccine vs Engerix-B Vaccine in Adults PROTECT Trial: Baseline Characteristics

Baseline Characteristic	PreHevbrio (n = 796)	Engerix-B (n = 811)
Age, mean (range), years	56.6 (18-86)	56.6 (18-90)
Male, no. (%)	315 (39.6)	303 (37.4)
Race, no. (%)		
White	715 (89.8)	730 (90.0)
Black/African American	66 (8.3)	65 (8.0)
Asian, Pacific Islander, Native Hawaiian, Al/AN	15 (1.8)	16 (2.0)
Current smoker, no. (%)	104 (13.1)	113 (13.9)
Type 2 diabetes, no. (%)	60 (7.5)	65 (8.0)
Country or region		
USA	338 (42.5)	342 (42.2)
Canada	126 (15.8)	133 (16.4)
Europe	332 (41.7)	336 (41.4)

HEPATITIS B

ONLINE


PreHevbrio Vaccine vs Engerix-B Vaccine in Adults PROTECT Trial: Week 28 Results (anti-HBs ≥10 mIU/mL), by Age Group



Source: Vesikari T, et al. Lancet Infect Dis. 2021;21:1271-81.


HEPATITIS B Online

PreHevbrio Vaccine vs Engerix-B Vaccine in Adults Aged **≥18 Years** PROTECT Trial: Results






PreHevbrio Vaccine vs Engerix-B Vaccine in Adults Aged **18-44 Years** PROTECT Trial: Results



HEPATITIS B

ONLINE


PreHevbrio Vaccine vs Engerix-B Vaccine in Adults Aged **45-64 Years** PROTECT Trial: Results



HEPATITIS B

ONLINE

PreHevbrio Vaccine vs Engerix-B Vaccine in Adults Aged ≥65 Years PROTECT Trial: Results




HEPATITIS B

ONLINE


PreHevbrio Vaccine vs Engerix-B Vaccine in Adults PROTECT Trial: Results (anti-HBs ≥100 mIU/mL), by Age and Gender

PreHevbrio Engerix-B



Source: Vesikari T, et al. Lancet Infect Dis. 2021;21:1271-81.

PreHevbrio Vaccine vs Engerix-B Vaccine in Adults PROTECT Trial: Results (anti-HBs ≥100 mIU/mL), by BMI, Diabetes, and Smoking





PreHevbrio Vaccine vs Engerix-B Vaccine in Adults ≥**18 years** PROTECT Trial: Results

Conclusions: "PreHevbrio was non-inferior to Engerix-B and induced higher seroprotection in adults aged 18 years of age and older after three doses of vaccine."





PreHevbrio versus Engerix-B in Healthy Adults, Age 18-45 CONSTANT Trial



PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Study Design

Design

 Phase 3, double-blind, randomized (1:1:1:1) controlled trial conducted in multiple centers in USA, Canada, Europe that assessed lot-to-lot consistency and immunogenicity of three consecutive PreHevbrio vaccine lots compared with one Engerix B vaccine lot in healthy adults

Subjects


- Participants: n = 2,838
- Ages: 18-45 years
- HBV vaccine naïve
- Exclusions: current or past HBV, HIV, HCV, immunosuppressed, pregnant or breastfeeding, live attenuated vaccine within prior 4 weeks; inactivated vaccine within prior 2 weeks; blood products / immunoglobulins within 90 days; eGFR <60 mL/min; BMP ≥35; HTN, diabetes mellitus, cancer

Primary End-Point

- Manufacturing equivalence of 3 independent consecutive lots, in terms of immunogenicity
- Immunogenicity measured by the geometric mean concentration (GMC) of anti-HBs concentrations 4 weeks after the third injection (day 196)



PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Design



Vaccine Dosing

PreHevbrio: 1.0 mL dose of 10 µg HBs antigens with aluminum adjuvant at weeks 0, 4, and 24 **Engerix-B**: 1 mL dose of 20 µg recombinant HBsAg with aluminum adjuvant at weeks 0, 4, and 24

Note: Each PreHevbrio arm represents an independent and different lot of vaccine



PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Baseline Characteristics

Baseline Characteristic	PreHevbrio (all) (n = 2,124)	Engerix-B (n = 712)
Age, mean (SD), years	33.5 (7.97)	33.4 (8.10)
Male, no. (%)	907 (42.7)	291 (40.9)
Race, no. (%) White Asian Black or African American American Indian or Alaska Native	1941 (91.4) 37 (1.7) 123 (5.8) 6 (0.3)	654 (91.9) 9 (1.3) 38 (5.3) 2 (0.3)
Current smoker, no. (%)	406 (19.1)	136 (19.1)
BMI, mean (SD)	25.9 (4.12)	25.7 (4.10)

HEPATITIS B Online


PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Results

GMC of HBV surface antibodies at Day 196	PreHevbrio Lot A (n = 620)	PreHevbrio Lot B (n = 622)	PreHevbrio Lot C (n = 627)
GMC, mean (SD)	5883.9 (5.4)	4824.1 (6.3)	5506.0 (6.0)
Mean adjusted GMC (SE) [95% CI]	5882.3 (1.1) [5112.4-6768.0]	4821.7 (1.1) [4190.1-5548.4]	5570.0 (1.1) [4844.6- 6403.7]
Adjusted GMC ratio (95% CI) Lot A vs. Lot B= 0.82 (0.67-1.00) Lot A vs. Lot C = 0.95 (0.78-1.15) Lot B vs. Lot C = 1.16 (0.95-1.41)			

Abbreviations: Geometric mean concentration; SD = standard deviation; SE = standard error; CI= confidence intervals




PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Results





PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Results



PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Adverse Reactions

Adverse Event (AE), no. (%)	PreHevbrio (n = 2,124)	Engerix-B (n = 712)
Any local reaction n (%)	1805 (85.0)	469 (65.9)
Systemic reaction, any, n (%)	1445 (68.0)	428 (60.1)
Serious AE (Grade 3 or 4), n (%) Participants with ≥1 unsolicited serious AE Vaccine-Related serious AE	42 (2.0) 0 (0)	3 (0.4) 0 (0)

Most common reactions: pain and tenderness (local); headache, fatigue, myalgia (systemic)



PreHevbrio Vaccine vs Engerix-B Vaccine in Healthy Adults Age 18-45 years CONSTANT Trial: Conclusions

Conclusions: "Among persons aged 18 to 45 years, consistently higher antibody concentrations and seroprotection rates were found among those vaccinated with PreHevbrio (all 3 lots) when compared to Engerix-B, after 2 and 3 doses."





Hepatitis B Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.







The content in this presentation is that of the author(s) and does not necessarily represent the official position of the Centers for Disease Control and Prevention.